Ultragenyx (RARE) Q1 2026 earnings review
Top-Line Reverses as Flagship Drug Stumbles
Ultragenyx broke its multi-year commercial growth streak with a 2% YoY revenue decline in 26Q1, entirely driven by a surprising 10% YoY drop in its flagship product, Crysvita. Management brushed this off as 'expected seasonality' and 'ordering patterns', but a year-over-year decline fundamentally contradicts the growth narrative. Consequently, the net loss widened to $185M and operating cash burn accelerated to $197M. Despite digging a deep hole in Q1, management stubbornly reaffirmed their aggressive FY26 revenue guidance ($730-$760M), which now demands an immediate and steep sales acceleration for the remainder of the year to achieve their 2027 profitability mandate.
🐂 Bull Case
The company has two PDUFA dates set for late 2026: DTX401 for GSDIa in August and the resubmitted UX111 for MPS IIIA in September. Approval of these gene therapies would open significant new revenue streams.
Evkeeza continues to outperform, jumping 64% YoY to $18M in Q1 driven by new country launches and early access demand. It is proving to be a reliable secondary growth engine.
🐻 Bear Case
Crysvita sales dropped 10% YoY. If Latin American ordering patterns and US/Canada royalties do not immediately rebound, the company will severely miss its 2026 financial targets.
The company burned $197M in operating cash this quarter, leaving $534M on the balance sheet. If revenue fails to accelerate, the 2027 profitability target looks mathematically out of reach without further dilution.
⚖️ Verdict: 🔴
Bearish. Explaining away a year-over-year decline in your primary cash-cow product as 'seasonality' is a major red flag. The math required to hit FY26 guidance now looks exceptionally strained against a backdrop of accelerating cash burn.
Key Themes
Data Contradiction: Crysvita 'Seasonality' Masks YoY Decline
Reversing. Management attributed Crysvita's weak $93M quarter to 'expected seasonality' in the US/Canada and 'ordering patterns in Brazil'. However, comparing the exact same seasonal period last year (25Q1), Crysvita generated $103M. US/Canada royalty revenue dropped from $41M to $39M YoY, and Latin America/Türkiye product sales plunged from $55M to $46M YoY. A genuine seasonal dip applies sequentially (Q4 to Q1), but a year-over-year contraction indicates fundamental demand or execution issues.
Accelerating Cash Burn Raises Runway Questions
Decelerating financial stability. Net cash used in operations swelled to $197M in 26Q1, significantly worse than the $166M burned in 25Q1. While Q1 routinely features annual bonus payments, total cash and investments dropped sharply from $737M at the end of 2025 to just $534M. At the current burn rate, the company has roughly three quarters of runway unless revenue drastically accelerates or heavy cuts take effect.
Evkeeza Becoming a Reliable Growth Engine
Accelerating. Evkeeza revenue hit $18M in 26Q1, a 64% YoY increase from $11M in 25Q1. Management highlighted that this is driven by increased demand from new country launches and early access programs. It's the sole commercial bright spot in an otherwise disappointing quarter for the base business.
GTX-102 (Angelman Syndrome) Advancing to Phase 3 Validation
Stable progression. Long-term Phase 1/2 data for GTX-102 continues to show durable improvements across multiple domains with no recurring drug-related serious adverse events for patients on chronic treatment (averaging 3+ years). The pivotal Phase 3 Aspire study (129 patients) is on track for a crucial data readout in the second half of 2026, serving as the company's largest pipeline catalyst.
Gene Therapy Approvals Set for Q3 2026
Stable. Ultragenyx is staring down two critical PDUFA dates: August 23, 2026 for DTX401 (GSDIa) and September 19, 2026 for UX111 (MPS IIIA). Notably, the FDA informed the company that an Advisory Committee meeting is not anticipated for DTX401, removing one layer of regulatory risk prior to the decision date.
Other KPIs
Decelerating profitability trajectory. Operating expenses grew 8% YoY from $282M in 25Q1. This includes a $30M restructuring expense connected to the 10% workforce reduction announced last quarter, alongside $30M in non-cash stock-based compensation. To hit their 2027 profitability target, these expenses must compress sharply in the coming quarters.
Stable. Up slightly from $17M in 25Q1. Tracking closely to its steady historical performance, but representing only a minor piece of the total revenue pie.
Guidance
Accelerating implied growth. By reaffirming this guidance after generating only $136M in Q1, Ultragenyx is implicitly promising to average roughly $203M per quarter for the rest of the year (which would require near-record quarterly performances back-to-back-to-back). This represents an incredibly steep climb.
Accelerating implied growth. Reaffirmed despite a disastrous $93M print in Q1. The company must average ~$139M per quarter in Q2-Q4 to hit the midpoint, a figure it has only achieved in its strongest historical periods (like 25Q4).
Accelerating. With $18M booked in Q1, Dojolvi will also need to sequentially ramp up to average ~$29M over the next three quarters to hit the midpoint of this reaffirmed guidance.
Stable to Reversing. Management reiterated that these expenses will flatten or decline this year, and decrease by at least 15% in 2027. Given Q1 saw R&D spike to $187M (up $21M YoY), drastic cuts must materialize immediately to honor this guidance.
Key Questions
Crysvita YoY Decline Reality
You attributed the Q1 Crysvita print to 'seasonality' and 'ordering patterns', but revenue fell 10% compared to the exact same quarter last year. Why are LatAm and US royalty revenues shrinking year-over-year, and what specific leading indicators give you confidence to reaffirm the $500M+ full-year target?
Cash Runway and Profitability Bridge
Operating cash burn was almost $200M this quarter, leaving $534M on the balance sheet. Assuming the $30M restructuring charge was a one-time headwind, what is the expected normalized cash burn for the remainder of the year, and do you anticipate needing to access the capital markets before reaching your 2027 profitability goal?
Restructuring Expense Impact
You booked a $30M restructuring expense in Q1 following last quarter's 10% workforce reduction. Have the operational disruptions associated with this layoff impacted commercial execution, specifically regarding the Crysvita miss?